Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Total Review Period for Standard Products Reduced by 4.5 Months to 14.7 Months: PMDA
July 18, 2011
- Positive PII Results for Takeda's TAK-875 Presented at ADA
July 18, 2011
- Ryukaikon Calls For Further Studies on Bar Code Labeling
July 18, 2011
- Committee Starts Discussing Relief System for Victims of Health Hazards Caused by Anticancer Drugs
July 18, 2011
- Positive Results for Central Neuropathic Pain with Lyrica in PIII Trial: Pfizer
July 18, 2011
- SymBio Licenses Rigosertib from Onconova for MDS
July 18, 2011
- Takeda Recalls Actos, Competact in France
July 18, 2011
- Combined with Insulin, Lixisenatide Decreases HbA1c
July 18, 2011
- Hisamitsu to Launch Norspan Tape in Early August Aiming for ¥1.3 Bil. Sales in FY2011
July 18, 2011
- Senju Files for Glaucoma Treatment Seen as Next-generation Strategic Product
July 18, 2011
- Eisai to Accelerate Biomarker Research with Its Subsidiary EIDIA
July 18, 2011
- Roche Returns Overseas Development, Marketing Rights for SGLT-2 Inhibitor to Chugai
July 18, 2011
- Pancreatic Cancer Approved as Add'l Indication for Tarceva: Chugai
July 18, 2011
- DPC Subcommittee to Look at Fixed-sum Reimbursement per Hospitalization for High-priced Drugs
July 18, 2011
- Further Consolidation of Dispensing Pharmacies Expected: Mr Ubunuki of Yano Research
July 18, 2011
- GSK Obtains Marketing Approval for Rotarix
July 18, 2011
- Taisei Kako Co-develops New Prefilled Syringe with Suzuken
July 18, 2011
- Kyowa Kirin to Enforce Safe Driver Education for New MRs
July 18, 2011
- 3 Products Including 4-Valent HPV Vaccine Gardasil Approved: MSD
July 18, 2011
- Nippon Kayaku Takes over Manufacturing Approval for Gelpart from Astellas
July 18, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…